Anthrax in Medical Technology

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

... antibody, for the prevention and treatment of anthrax infection. To date, the Company has received ... and is designed to protect against and treat anthrax infection, including inhalational anthrax, the ... to target a protein component known as the anthrax Protective Antigen (PA) of the lethal and edema ...

PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA

... a next generation recombinant protective antigen anthrax vaccine. The FDA submission is in response ... procure 25 million doses of a next generation rPA anthrax vaccine for the country's civilian biomedical ... and procurement of next generation rPA anthrax vaccines." About SparVax(TM) SparVax(TM) ...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

... - First-in-class treatment for inhalation anthrax - ROCKVILLE, Md., May 21 ... upon FDA licensure of raxibacumab. About anthrax anthrax infection is caused by a spore-forming bacterium, ...

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

... 4:30 p.m. E.T., to review the status of its rPA anthrax vaccine program. The dial-in number within ... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human ...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

... Survival in Animals with Clinical Symptoms of anthrax disease - PINE BROOK, N.J., April 20 ... and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen. (Logo: ... demonstrates remarkable efficacy in treating anthrax infection in animal models and is a strong ...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... data have shown that in addition to inhibiting anthrax toxin, Valortim(R) augments the immune system's ability to kill anthrax bacilli. In an in vitro mouse macrophage ... that Valortim(R) can enhance the killing of anthrax by human dendritic cells. Dr. Cross ...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

... step forward in the treatment of inhalation anthrax and could play an important role in strengthening ... ABthrax represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the ...

PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop

... Antibody, in the Treatment of Inhalation anthrax in the African Green Monkey Model," investigators ... 21 adult AGMs were exposed by aerosol to Ames anthrax spores and blood samples were collected every 4-8 hours beginning 24-hours post exposure to assess anthrax bacteremia and protective antigen in blood. ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... launch in 2010 - - ABthrax(TM) for inhalation anthrax on track to begin delivery fall 2008 - - ... after animals were already showing symptoms of anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores. These dramatic and statistically ...

New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies

... administered after animals were symptomatic for anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores. These dramatic and ... HGS. ABthrax, which specifically targets anthrax toxins and is being developed under contract with ...

Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic

... has developed a highly effective and valuable anthrax therapeutic for procurement under Project ... Dr. Posillico continued, "Inhalation of anthrax spores rapidly leads to death if patients are not ... antibiotics. Typically, victims of inhalation anthrax experience only vague symptoms until it is too ...

ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

... VaxGen's Recombinant Protective Antigen anthrax Vaccine to be tested with ... pharmaceutically active ingredient of VaxGen's anthrax vaccine candidate, recombinant ... of the MTA were not disclosed. VaxGen's rPA102 anthrax vaccine is composed of a purified rPA and ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward ... development is raxibacumab (ABthrax(TM)) for the treatment of inhalation anthrax (Biologics License Application currently pending with the U.S. Food and ...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

... is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 ... ABthrax offers a significant step forward in the treatment of inhalation anthrax and could play an important role in strengthening America's arsenal ...

Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Hospital Launches Landmark Emergency Medicine Project

... the facility took on greater urgency following the events of 9/11 and the anthrax attacks of 2001. Washington Hospital Center was one of the few hospitals ... treated hundreds of patients who feared possible anthrax exposure after anthrax was found on Capitol Hill and in a local postal facility. However the $75 ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of ...

Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule

... development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary ... to purchase 20,000 doses of ABthrax(TM) (raxibacumab) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL ...

Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents

... that cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the current standard of care, Cipro(R) (ciprofloxacin), ... was also recently shown to be effective in preventing inhalation anthrax (Bacillus anthracis) infection post-exposure in a primate study. ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

... drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon ...

Nation's Laboratory Response Network Marks First Decade of Protecting Public Health

... training its laboratorians in emergency response measures, a Florida LRN reference lab identified Bacil l us anthraci s , the index case for the anthrax events of 2001, in a clinical specimen," remembers APHL Executive Director Scott Becker. "That day the concept of a national, rapid response ...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... Linezolid- and Methicillin-Resistant Staphylococcus aureus cfr Strain CM/05 -- F1-2066: Demonstration of TR-701 Efficacy in a Mouse Inhalation anthrax Model -- F1-2067: Absence of a Pressor Response to Oral Tyramine in Conscious Telemeterized Rats Treated with the Novel Oxazolidinone ...

Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

... treatment of inhalation anthrax post- exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. About Advanced Life Sciences Advanced Life Sciences is a ...

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH

... a biological containment facility, or an intentional release of a weaponized or bioterrorist-modified pathogen designed to cause diseases such as anthrax or smallpox. Initial research testing demonstrated 100% protection of mice against a lethal challenge with an H3N2 influenza virus after a single 2 ...

Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist

... plants. Dr. Nash also developed tests for strep, whooping cough, salmonella, toxins and other diagnostics. During the first Gulf War, he worked on anthrax tests until government funding dissipated. Along with two others, Dr. Nash spun off Camas Inc. From the University Technical Center in Minneapolis, ...

Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin

... treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post-exposure, but the drug is not yet approved for this or any other indication. About Advanced Life Sciences Advanced Life Sciences is a ...

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia

... treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. About John Bartlett, M.D. Dr. Bartlett is a Professor of Medicine ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... the potency of cethromycin as a potential treatment against bioterrorism pathogens: "Efficacy of Cethromycin Against a Lethal Inhalation anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained normal hematologic parameters and remained abacteremic throughout the ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... the potency of cethromycin as a potential treatment against bioterrorism pathogens: "Efficacy of Cethromycin Against a Lethal Inhalation anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained normal hematologic parameters and remained abacteremic throughout the ...

Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... 222: Pathogenesis and Therapeutics in Agents of Bioterrorism -- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal Inhalation anthrax Challenge in Rhesus Macaques Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D Poster Session 176: Macrolides, Ketolides, ...

Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

... developed for the prevention and treatment of anthrax infection, has been shown to have a therapeutic ... in a new primate model of established inhalation anthrax infection. The new model, which is being ... to improve on existing therapeutic models for anthrax by closely monitoring the disease process to ...